EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which…
Conditions studied
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
About this study
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- Drug: Vicadrostat — Vicadrostat
- Drug: Empagliflozin — Empagliflozin
- Drug: Placebo matching Vicadrostat — Placebo matching Vicadrostat
Primary outcomes
- Time to first event of cardiovascular (CV) death or heart failure event (HFE) (Up to 51 months)
Eligibility information
Study locations
- Pinnacle Research Group, LLC, Anniston, Alabama 36207 United States
- Eastern Shore Research Group, Fairhope, Alabama 36532 United States
- Lakeview Clinical Research, Guntersville, Alabama 35976 United States
- Arizona Clinical Trials - Chandler, Chandler, Arizona 85225 United States
- Elite Clinical Studies, Phoenix, Arizona 85018 United States
- Clinical Research Institute of Arizona, LLC, Sun City West, Arizona 85375 United States
- Fiel Family & Sports Medicine, Tempe, Arizona 85283 United States
- Arizona Clinical Trials, Tucson, Arizona 85711 United States
- Yuma Clinical Trials, Yuma, Arizona 85364 United States
- National Heart Institute, Beverly Hills, California 90211 United States
Showing 10 of 1142 reported sites. See the official listing for all locations.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.